Curevac N.V. (CVAC) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CureVac N.V., in partnership with GSK, reports encouraging interim results from their Phase 2 study on a seasonal influenza vaccine candidate, revealing significant antibody response across all flu strains and age groups. The candidate vaccine, which includes antigens for all four WHO-recommended flu strains, also demonstrated a strong safety profile, with plans to further optimize responses against influenza B strains in upcoming studies.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.